NOV 0 5 7004 E

P

Sheet 1 of 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 3613/1/US APPLICATION NO.: 10/727,918

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

INVENTOR: Stephen P. Arneric

(Use several sheets if necessary)

Filed: : 12/04/2003

Group: 1646

U.S. PATENT DOCUMENTS

Examiner		Documet					Filing Date If
Initial		Number	Date	Name	Class	Subclass	Appropriate
/C.S./	1	5,434,178	06/18/95	Talley, et al.	514	406	11/30/93
	2	5,476,944	12/19/95	Partis, et al.	514	357	05/19/94
	3	5,643,933	07/01/97	Talley, et al.	514	372	06/2/95
	4	5,859,257	01/12/99	Talley, et al.	548	247	08/14/96
	5	5,932,598	08/03/99	Talley, et al.	514	341	01/12/98
	6	6,156,781	12/05/00	Talley, et al.	514	406	11/24/99
	7	6,110,960	08/29/00	Janusz, et al.	514	432	06/06/97
	8	6,180,651 B1	01/30/01	Nicolai	514	336	09/19/98
	9	5,521,207	05/28/96	Graneto	514	406	04/06/94
	10	5,760,068	01/02/98	Talley, et al.	5Ì4	403	06/08/95
	11	2001/0029257	10/11/01	Murdock	514\	220	10/11/01
	12	4,229,449	10/21/80	Melloni, et al.	424	248.58	01/08/79
	13	6,465,458 B1	10/15/02	Wong, et al.	514	239	06/22/00
	14	6,290,986 B1	09/18/01	Murdock, et al.	424	449	06/29/98
	15	6,229,010 B1	05/08/01	Crocker, et al.	544	1.32	12/09/98
	16	6,096,742 B1	08/01/00	Crocker, et al.	514	241	12/15/98
	17	6,117,855	09/12/00	Carison, et al.	514	90	10/17/98
	18	6,066,643	05/23/00	Perry	514	239	09/17/98
	19	6,028,070	02/02/00	Heiligenstein	514	238.8	09/17/98
1/_	20	6,046,193	04/04/00	Heiligenstein	514	239	09/17/98
V	21	6,034,256	05/07/00	Carter, et al.	549	456	04/17/98

FOREIGN PATENT DOCUMENTS

Examiner Initial		Documet Number	Date	Name	Class	Subclass	Filing Date If Appropriate
/C.S./_	22	WO 00/24719	05/04/00	Black, et al.	237	14	10/27/99
	23	WO 002/102297	12/27/02	Muller, et al.	A61K	*******	05/31/02
	24	WO 0101973	01/11/01	Wong, Eric, H.F.	31	00	06/22/04
	25	WO 0115687	03/08/01	Stoner, et al.	31	18	12/24/00
	26	WO 9847890	10/30/03	Stephenson, et al.	31	35	04/14/03
	27	WO 9911605	03/11/99	Novartis- Efrfindungen, et al.	229	42	08/26/97
	28	WO 03088958	10/29/98	Carter, et al.	311	58	04/18/98
	29	WO 0162236	08/30/01	Rogosky, et al.	· 31	00	01/23/01

EXAMINER	/Chris Simmons/ (04/12/2007)	DATE CONSIDERED	04/12/2007			
EXAMINER:	EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609.					
Draw line through citation if not in conformance and not considered. Include copy of this form with						
next communic	next communication to applicant.					

(Form PTO-1449)

Sheet 2 of 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 3613/1/US	APPLICATION NO.: 10/727,918	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	INVENTOR: Stephen P. Arneric		
(Use several sheets if necessary)	Filed: 12/04/2003	Group: 1646	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial	TARBOTO CONTENTS (Including Nutrior) True, Date, 1 of timent 1 ages, Liter)						
/C.S./	30	Needleman, P., et al., J. Rheumatol., 24, Suppl. 49.6 - 8 (1997).					
	31	Fu, J. Y., et al., J. Biol. Chem., 265(28): 16737-40 (1990).					
	32	Samad., T. A., et al., Nature, 410(6827):471-5 (2001).					
	33	Buttgereit, F., et al., Am. J. Med., 110(3 Suppl. 1):13-9 (2001).					
	34	Osiri, M., et al., Mayo Clin. Proc., 75(10):1027-38 (2000).					
	35	Wollheim, F.A., Current Opin. Rheumatol., 13:193-201 (2001).					
	36	Hillson, J. L., et al., Expert Opin Pharmacother., 1(5):1053-66 (2000).					
	37	Everts, B., et al., Clin. Rheumatol., 19(5):331-43 (2000).					
	38	Jamali, F., J. Pharm. Pharm. Sci., 4(1):1-6 (2001).					
	39	Saag, K., et al., Arch. Fam. Med., 9(10):1124-34 (2000).					
	40	Yoshimi, N., et al., in Japanese J. Cancer Res., 90(4):406-412 (1999).					
	41	Iwata, K., et al., in Jpn. J. Pharmacol., 75(2):191-194 (1997).					
	42	The Pharmacologist Basis of Therapeutics, Ninth Edition (1996), Appendix II, pp. 1707-1711.					
	43	Winter, et al., (Proc. Soc. Exp. Biol. Med., 111, 544 (1962)).					
	44	Otterness and Bliven, Laboratory Models for Testing NSAIDS, in Non-steroidal Anti-Inflammatory Drugs, (J. Lombardino, ed. (1985)).					
45 Hargreaves, et al., (I		Hargreaves, et al., (Pain, 32, 77 (1988)).					
46 J. Stuart, Annual Rev. Immunol., 2, 199 (1984).		J. Stuart, Annual Rev. Immunol., 2, 199 (1984).					
47 P. Wooley, et al., trans. Proc., 15, 180 (1983).		P. Wooley, et al., trans. Proc., 15, 180 (1983).					
$\blacksquare \Psi \blacksquare$	48	R. Jonsson, J. Immunol. Methods, 88, 109 (1986).					

EXAMINER	/Chris Simmons/ (04/12/2007)	DATE CONSIDERED	04/12/2007				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609							
Draw line through	oh citation if not in conformance a	nd not considered. Inclu-	de conv of this form with				

Draw line through citation if not in conformance and not considered. Include copy of this fo next communication to applicant.

(Form PTO-1449)